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Effects of YM155 on survivin levels and viability in
neuroblastoma cells with acquired drug resistance
Yvonne Voges1,6, Martin Michaelis2,6, Florian Rothweiler1, Torsten Schaller1, Constanze Schneider1, Katharina Politt3,
Marco Mernberger3, Andrea Nist4, Thorsten Stiewe3,4, Mark N Wass2, Franz Rödel5 and Jindrich Cinatl*,1
Resistance formation after initial therapy response (acquired resistance) is common in high-risk neuroblastoma patients. YM155 is
a drug candidate that was introduced as a survivin suppressant. This mechanism was later challenged, and DNA damage induction
and Mcl-1 depletion were suggested instead. Here we investigated the efficacy and mechanism of action of YM155 in
neuroblastoma cells with acquired drug resistance. The efficacy of YM155 was determined in neuroblastoma cell lines and their
sublines with acquired resistance to clinically relevant drugs. Survivin levels, Mcl-1 levels, and DNA damage formation were
determined in response to YM155. RNAi-mediated depletion of survivin, Mcl-1, and p53 was performed to investigate their roles
during YM155 treatment. Clinical YM155 concentrations affected the viability of drug-resistant neuroblastoma cells through
survivin depletion and p53 activation. MDM2 inhibitor-induced p53 activation further enhanced YM155 activity. Loss of p53
function generally affected anti-neuroblastoma approaches targeting survivin. Upregulation of ABCB1 (causes YM155 efflux) and
downregulation of SLC35F2 (causes YM155 uptake) mediated YM155-specific resistance. YM155-adapted cells displayed
increased ABCB1 levels, decreased SLC35F2 levels, and a p53 mutation. YM155-adapted neuroblastoma cells were also
characterized by decreased sensitivity to RNAi-mediated survivin depletion, further confirming survivin as a critical YM155 target
in neuroblastoma. In conclusion, YM155 targets survivin in neuroblastoma. Furthermore, survivin is a promising therapeutic target
for p53 wild-type neuroblastomas after resistance acquisition (neuroblastomas are rarely p53-mutated), potentially in combination
with p53 activators. In addition, we show that the adaptation of cancer cells to molecular-targeted anticancer drugs is an effective
strategy to elucidate a drug’s mechanism of action.
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Survivin, a member of the inhibitor of apoptosis protein (IAP)
family, comprises a nodal protein implicated in a multitude of
cellular pathways, including apoptosis and mitosis regulation,
and is frequently found highly expressed in cancer cells,
making it a potential target for anticancer therapies.1,2 Indeed,
a variety of survivin antagonists including YM155 entered
clinical evaluation. YM155 (sepantronium bromide) was
introduced as a transcriptional suppressor of survivin expres-
sion that displayed activity against a broad range of cancer
types in preclinical models.1,3 However, further studies
suggested that the YM155-induced inhibition of survivin
expression may be a secondary effect downstream of
YM155-induced DNA damage1,4,5 or associated with Myeloid
Cell Leukemia 1 (Mcl-1) depletion.6
Herewe investigated themechanism of action of YM155 in a
panel consisting of the neuroblastoma cell lines UKF-NB-3
and UKF-NB-6 and their sublines with acquired resistance to
cisplatin (UKF-NB-3rCDDP1000), doxorubicin (UKF-NB-6rDOX20),
or vincristine (UKF-NB-3rVCR10 and UKF-NB-6rVCR10).
Neuroblastoma is the most frequent solid extracranial
pediatric cancer entity. About half of the patients are
diagnosed with high-risk disease associated with overall
survival rates below 50%, despite myeloablative therapy and
differentiation therapy using retinoids.7,8 Although many
neuroblastomas respond initially well to therapy, acquired
drug resistance represents a major obstacle in clinical
practice.7,8 Survivin had been previously shown to be a
potential drug target in neuroblastoma.9–13 However, survivin
had not been investigated as a therapeutic target in the
acquired resistance setting in neuroblastoma prior to this
study. Our principal findings are that survivin is a promising
drug target in p53 wild-type neuroblastoma cells with acquired
drug resistance and that YM155 impairs neuroblastoma cell
viability in clinically achievable concentrations via survivin
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depletion. The drug-resistant cell lines displayed decreased
sensitivity to YM155, with upregulation of the ATP-binding
cassette (ABC) transporter ATP Binding Cassette Subfamily B
Member 1 (ABCB1, also known as P-glycoprotein or multidrug
resistance gene 1, MDR1; causes cellular YM155 efflux) and
downregulation of Solute Carrier Family 35 Member F2
(SLC35F2, mediates cellular YM155 uptake) as the major
drug-specific resistance mechanisms and loss of p53 function
as resistance mechanism that affects all approaches targeting
survivin in neuroblastoma. In accordance with these findings,
neuroblastoma cells adapted to YM155 displayed decreased
levels of SLC35F2, increased levels of ABCB1, a p53
mutation, decreased levels of survivin, and decreased
sensitivity to RNAi-mediated survivin depletion.
Results
Effects of YM155 on neuroblastoma cell viability. Treat-
ment of the neuroblastoma cell lines UKF-NB-3 and UKF-NB-6
with YM155 resulted in IC50 values of 0.49 and 0.65 nM,
respectively (Figure 1a and Supplementary Table 1). The
UKF-NB-3 sublines with acquired resistance to cisplatin
(UKF-NB-3rCDDP1000) or vincristine (UKF-NB-3rVCR10), as
well as the UKF-NB-6 sublines resistant to doxorubicin
(UKF-NB-6rDOX20) or vincristine (UKF-NB-6rVCR10), displayed
substantially reduced YM155 sensitivity compared to the
parental cell lines, resulting in IC50 values ranging from
5.32 nM (UKF-NB-3rCDDP1000) to 49.3 nM (UKF-NB-6rVCR10)
(Figure 1a and Supplementary Table 1). There was no
correlation between the YM155 IC50 and the survivin expres-
sion levels (Supplementary Figure 1).
ABCB1 expression decreases YM155 efficacy in neuro-
blastoma cells. ABCB1 expression was previously shown to
interfere with YM155 efficacy.10,14 Among the investigated cell
lines, UKF-NB-3rVCR10, UKF-NB-6rDOX20, and UKF-
NB-6rVCR10 display detectable ABCB1 activity (Figure 1b
and Supplementary Figure 2). In accordance, the ABCB1
inhibitor verapamil reduced the YM155 IC50s in these cell
lines (Figure 1c and Supplementary Table 1). Furthermore,
UKF-NB-3 and UKF-NB-6 cells transduced with a lentiviral
vector encoding for ABCB1 demonstrated strongly increased
resistance to YM155 (Figure 1d and Supplementary Figure 2).
However, treatment of the ABCB1-expressing cell lines UKF-
NB-3rVCR10, UKF-NB-6rDOX20, and UKF-NB-6rVCR10 with
the ABCB1 inhibitor verapamil did not reduce the YM155
IC50s to the level of parental UKF-NB-3 or UKF-NB-6 cells
(Figure 1c and Supplementary Table 1). This indicates that
other mechanisms in addition to ABCB1 expression interfere
with YM155 efficacy in the resistant cell lines.
Reduced SLC35F2 levels contribute to decreased YM155
sensitivity in drug-resistant neuroblastoma cells. The
solute carrier SLC35F2 was shown to mediate cellular uptake
of YM155.15 Reduced SLC35F2 levels were detected in UKF-
NB-3rCDDP1000, UKF-NB-6rDOX20, and UKF-NB-6rVCR10
cells (Figure 1e and Supplementary Figure 2). Hence,
decreased SLC35F2 levels appear to contribute to YM155
resistance in these cell lines. In accordance, RNAi-mediated
depletion of SLC35F2 reduced the YM155 sensitivity of UKF-
NB-3 cells (Figure 1f and Supplementary Table 2) and further
increased the YM155 resistance of ABCB1-transduced UKF-
NB-3 and UKF-NB-6 cells (Figure 1g and Supplementary
Table 3).
p53 status influences neuroblastoma cell sensitivity to
YM155. In contrast to the other ABCB1-expressing neuro-
blastoma cell lines UKF-NB-6rDOX20 and UKF-NB-6rVCR10,
the vincristine-resistant UKF-NB-3 subline UKF-NB-3rVCR10
did not display decreased levels of SLC35F2 (Figure 1e),
although it was not resensitized to YM155 to the level of the
respective parental cell line UKF-NB-3 by the ABCB1 inhibitor
verapamil (Figure 1b and Supplementary Table 1). An
important difference between UKF-NB-3rVCR10 and the other
investigated neuroblastoma cell lines is that UKF-NB-3rVCR10
cells harbor a C135F p53 mutation.16–18 Indeed, YM155
induced a p53 response in UKF-NB-3 and UKF-NB-6 cells as
indicated by increased cellular levels of p53 and p21, and
apoptosis as indicated by poly(ADP-ribose) polymerase
(PARP) cleavage (Figure 2a). Moreover, p53-depleted UKF-
NB-3 and UKF-NB-6 cells displayed no activation of p53
signaling and substantially decreased sensitivity in response
to YM155 (Figures 2a and b and Supplementary Table 4).
Similar results were obtained for the nutlin-3-resistant UKF-
NB-3 subline UKF-NB-3rNutlin10μM (Supplementary Table 4)
that harbors a G245C loss-of-function p53 mutation.18
In order to determine whether additional activation of p53
may further increase YM155 activity, we combined YM155
with nutlin-3 that activates p53 through Mouse Double Minute
2 (MDM2) inhibition.19 Indeed, nutlin-3 increased the antic-
ancer effects of YM155 (Figure 3a) and p53 signaling
(Figure 3b and Supplementary Figure 3), suggesting that
p53 activation plays a pivotal role within the anticancer effects
of YM155.
YM155 interferes with neuroblastoma cell viability
through survivin depletion. The anticancer mechanism of
action of YM155 is under dispute. The compound was
introduced as a suppressor of survivin expression. However,
this mechanism was challenged and some studies suggested
that the YM155-induced inhibition of survivin expression may
be a secondary effect downstream of YM155-induced DNA
damage.1,3,4
In order to determine the mechanism of action of YM155 in
our model system, we determined the kinetics of cellular
survivin levels and DNA damage in response to YM155
treatment over time. Although survivin depletion became
visible after 14 h of treatment at an YM155 concentration of
5 nM, a substantial increase of the phosphohistone γ-histone
H2A (γH2AX) levels indicating DNA double-strand breaks
became only detectable after 24 h at YM155 concentrations of
10 nM or higher (Figure 4 and Supplementary Figure 4). In
accordance, a DNA damage kit that determines apurinic/
apyrimidinic sites as indicators of DNA lesions by using an
Aldehyde Reactive Probe (PromoKine, Heidelberg, Germany)
did only detect DNA damage in UKF-NB-3 cells after 24 h of
YM155 (10 nM) treatment but not after 14 h of YM155 (10 nM)
treatment (Supplementary Figure 5). This shows that YM155-
induced suppression of survivin expression precedes DNA
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Figure 1 Effects of YM155 on neuroblastoma cell viability and the role of ABCB1 and SLC35F2 expression. (a) YM155 concentrations that reduce the viability of the
investigated neuroblastoma cell lines by 50% (IC50) as determined by MTTassay after a 120 h incubation period (numerical values are presented in Supplementary Table 1).
*Po0.05 relative to the respective parental cell line; (b) Cellular ABCB1 levels as indicated by quantitative, fluorescence-based western blot analysis; values are presented as
fold change relative to the respective parental cell line. Representative western blots are provided in Supplementary Figure 2. *Po0.05 relative to the respective parental cell line;
(c) YM155 IC50s as determined by MTTassay after a 120 h incubation period in the presence of the ABCB1 inhibitor verapamil (5 μM) in the parental cell lines UKF-NB-3 and
UKF-NB-6 and their ABCB1-expressing sublines UKF-NB-3rVCR10, UKF-NB-6rDOX20, and UKF-NB-6rVCR10 (numerical values are presented in Supplementary Table 1).
*Po0.05 relative to the respective parental cell line; (d) YM155 IC50s as determined by MTTassay after a 120 h incubation in UKF-NB-3 or UKF-NB-6 cells transduced with a
lentiviral vector encoding for ABCB1 or an empty control vector (piCER2). *Po0.05 relative to the respective control vector-transduced cell line; (e) Cellular SLC35F2 levels as
indicated by quantitative, fluorescence-based western blot analysis; values are presented as fold change relative to the respective parental cell line. Representative western blots
are provided in Supplementary Figure 2. *Po0.05 relative to the respective parental cell line; (f) Western blot indicating SLC35F2 depletion in UKF-NB-3 cells by three lentiviral
vectors encoding for shRNA directed against three different sequences of SLC35F2 (sh1 SLC, sh2 SLC, sh3 SLC) relative to untreated and empty control vector-treated (control)
UKF-NB-3 cells and bar chart indicating YM155 concentrations that reduce the viability of these cell lines by 50% (IC50) as indicated by MTT assay after 120 h of incubation.
Numerical IC50 values are presented in Supplementary Table 2. *Po0.05 relative to non-treated cells; (g) Western blots indicating siRNA-mediated SLC35F2 depletion (scr
siRNA, non-targeting ‘scrambled’ siRNA) and bar chart displaying YM155 IC50 values (as indicated by MTTassay after 120 h of incubation) in UKF-NB-3 and ABCB1-transduced
UKF-NB-3 (UKF-NB-3ABCB1) cells with or without transfection by siRNA directed against SLC35F2. Numerical values and controls transfected with non-targeting siRNA are
presented in Supplementary Table 3. *Po0.05 relative to the respective non-transfected cells
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damage formation. RNAi-mediated survivin depletion resulted
in an increase of γH2AX levels and Checkpoint Kinase 2
(Chk2) phosphorylation in UKF-NB-3 and UKF-NB-6 cells
(Figure 5a), demonstrating that survivin depletion is sufficient
to induce DNA damage in our system. The notion that YM155-
induced survivin depletion is not a consequence of DNA
damage induction in neuroblastoma cells was further sup-
ported by data showing that irradiation-induced DNA damage
did not decrease the survivin levels in UKF-NB-3 cells but
rather resulted in enhanced survivin levels, both in the
presence and in the absence of p53 (Figure 6a and
Supplementary Figure 6). p53-depleted UKF-NB-3 cells were
substantially more resistant to irradiation than UKF-NB-3 cells
(Figure 6b), but, notably, YM155 increased the anti-
neuroblastoma effects of irradiation in UKF-NB-3 cells and
p53-depleted UKF-NB-3 cells (Figure 6c).
Neuroblastoma cells without functional p53 had been
shown to be less sensitive to YM155 than neuroblastoma
cells with functional p53 (Figures 2 and 3). In concordance,
YM155 treatment resulted in delayed survivin depletion and
DNA double-strand break formation in p53-depleted UKF-
NB-3 cells compared to wild-type p53-expressing UKF-NB-3
cells (Supplementary Figures 4 and 7). Reduced survivin
levels became detectable in p53-depleted UKF-NB-3 cells
only after 18–24 h of YM155 treatment. DNA damage as
indicated by γH2AX levels was (in contrast to YM155-treated
UKF-NB-3 cells) not detected after 24 h treatment of p53-
depleted UKF-NB-3 cells with YM155 concentrations of up to
25 nM (Supplementary Figures 4 and 7). YM155-induced
survivin depletion became visible in p53-depleted UKF-NB-3
cells only after 48 h of YM155 treatment (Figure 5b and
Supplementary Figure 8). DNA damage induction was only
detected at YM155 concentrations of 10 and 25 nM after 48 h
of treatment (Figure 5b and Supplementary Figure 8). In
accordance, p53-depleted UKF-NB-3 cells and p53-mutant
UKF-NB-3rVCR10 were less sensitive to siRNA-mediated
survivin depletion than UKF-NB-3 cells (Figure 5c and
Supplementary Table 5).
Mcl-1 was suggested to be an additional target of YM155.6
Compared to YM155-mediated survivin depletion, we
detected reduced Mcl-1 levels only in response to substan-
tially higher YM155 concentrations and at later time points
Figure 2 Relevance of functional p53 for the YM155-mediated anti-neuroblastoma effects. (a) Protein levels of p53, p21, γH2AX, H2AX, phosphorylated Chk2 (pChk2), Chk2,
cleaved PARP (cl. PARP), Mcl-1, cIAP-1, cIAP-2, XIAP, and survivin after YM155 (25 nM) treatment for 24 h of non-transduced UKF-NB-3/UKF-NB-6 cells (Control), UKF-NB-3/UKF-
NB-6 cells transduced with a lentiviral vector encoding for shRNA targeting p53 (p53 shRNA), or UKF-NB-3/UKF-NB-6 cells transduced by a control vector encoding for non-targeting
(‘scrambled’) shRNA (scr shRNA); β-actin served as loading control. (b) YM155 concentrations that reduce neuroblastoma cell viability by 50% (IC50) in UKF-NB-3 and UKF-NB-6
cells in the absence or presence of functional p53; p53 was depleted using a lentiviral vector encoding for shRNA targeting p53 (UKF-NB-3p53shRNA and UKF-NB-6p53shRNA).
Numerical values and control cell lines transduced with non-targeting shRNA are presented in Supplementary Table 4. *Po0.05 relative to the respective non-transduced cell
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Figure 3 Effects of p53 activation by the MDM2 inhibitor nutlin-3 on the YM155-induced effects on neuroblastoma cell viability. (a) Effects of nutlin-3 (1 μM), YM155
(0.625 nM), or their combination on neuroblastoma cell viability as indicated by MTTassay after 120 h incubation. *Po0.05 relative to either single treatment; n.d.= no detectable
cell viability; (b) Representative western blots indicating the effects of combined YM155 and nutlin-3 treatment on p53 signaling (p53 and p21 levels), DNA damage (γH2AX
levels), and survivin levels in UKF-NB-3 and UKF-NB-6 cells after 24 h of incubation. The respective quantitative data are provided in Supplementary Figure 3
Figure 4 Kinetics of survivin depletion and DNA damage induction by YM155 in neuroblastoma cells. Levels of survivin and γH2AX (indicating DNA damage) in UKF-NB-3
cells in response to YM155 treatment after 14 or 24 h as indicated by quantitative, fluorescence-based western blot analysis; values are presented as fold change relative to the
respective parental cell line. Detailed kinetics and representative western blots are provided in Supplementary Figure 4. *Po0.05 relative to untreated control
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(Supplementary Figure 9). Moreover, Mcl-1 depletion did (in
contrast to survivin depletion) not affect UKF-NB-3 cell viability
(Supplementary Figure 10), suggesting that YM155-mediated
survivin depletion is critical for the compound’s effects on
neuroblastoma cell viability. The Mcl-1 levels are not regulated
by survivin since survivin depletion did not decrease the Mcl-1
levels in UKF-NB-3 and UKF-NB-6 cells (Figure 5a).
Taken together, these findings demonstrate that survivin
is a critical target in neuroblastoma cells, that the anti-
neuroblastoma effects of YM155 involve survivin
depletion (prior to DNA damage induction), and that p53 is
involved in mediating anti-neuroblastoma effects as a con-
sequence of RNAi- or YM155-induced reduction of cellular
survivin levels.
Figure 5 Effects of siRNA-mediated survivin depletion on neuroblastoma cell viability. (a) Western blots indicating levels of γH2AX, H2AX, phosphorylated Chk2 (pChk2),
Chk2, cleaved PARP, Mcl-1, cIAP-1, cIAP-2, XIAP, or survivin in neuroblastoma cells, neuroblastoma cells transfected with non-targeting control siRNA, and neuroblastoma cells
transfected with siRNA targeting survivin (BIRC5) 24 h post transfection. β-actin served as loading control. (b) Levels of survivin and γH2AX (indicating DNA damage) in UKF-
NB-3 cells transduced with a lentiviral vector encoding for shRNA targeting p53 (UKF-NB-3p53shRNA) in response to YM155 treatment for 48 h as indicated by quantitative,
fluorescence-based western blot analysis; values are presented as fold change relative to the respective parental cell line. Representative western blots are provided in
Supplementary Figure 4. (c) Viability of UKF-NB-3 cells, UKF-NB-3rVCR10 cells, and UKF-NB-3p53shRNA cells 48 h after transfection with siRNA targeting survivin (BIRC5);
Western blots indicating depletion efficiency in UKF-NB-3rVCR10 cells and UKF-NB-3p53shRNA cells are presented in Supplementary Figure 11. Numerical values including
controls transfected with non-targeting siRNA are shown in Supplementary Table 5
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Neuroblastoma cells adapted to YM155 display
reduced survivin and SLC35F2 levels, increased ABCB1
levels, a p53 mutation, and decreased sensitivity to
survivin depletion. Finally, we established a YM155-
resistant UKF-NB-3 cell line (UKF-NB-3rYM15520nM). UKF-
NB-3rYM15520nM cells displayed a 497-fold increased
resistance to YM155 (IC50: 303±8 nM) compared to parental
UKF-NB-3 cells (IC50: 0.61±0.08 nM) (Figure 7a and
Supplementary Table 6). Moreover, UKF-NB-3rYM15520nM
cells expressed increased levels of ABCB1, decreased levels
of SLC35F2 (Figure 7b), and harbored a R248W p53
mutation. This suggests that multiple resistance mechanisms
contribute to the acquired YM155 resistance phenotype
observed in these cells. In accordance, the ABCB1 inhibitor
verapamil (5 μM) sensitized UKF-NB-3rYM15520nM cells to
YM155 (IC50: 90.5±3.1 nM) but not to the level of parental
UKF-NB-3 cells (Figure 7a and Supplementary Table 6).
UKF-NB-3rYM15520nM cells also displayed reduced survi-
vin levels (Figure 7b) and reduced sensitivity to survivin
depletion relative to UKF-NB-3 cells (Figure 7c and
Supplementary Table 5). This further confirmed that survivin
is a primary target of YM155 in neuroblastoma.
Discussion
Here we investigated the efficacy of the survivin suppressant
YM155 in a panel of neuroblastoma cell lines consisting of the
V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblas-
toma Derived Homolog (MYCN)-amplified neuroblastoma cell
lines UKF-NB-3 undUKF-NB-6 and their sublineswith acquired
resistance to cisplatin (UKF-NB-3rCDDP1000), doxorubicin
(UKF-NB-6rDOX20), and vincristine (UKF-NB-3rVCR10 and
UKF-NB-6rVCR10). The YM155 IC50 values ranged from
0.49 nM (UKF-NB-3) to 49.3 nM (UKF-NB-6rVCR10). This is in
the range of therapeutically achievable plasma levels that were
documented to reach about 50 nM.20–22 Notably, animal
models indicated that the YM155 concentrations in tumor
tissues are likely to be higher than those found in the
plasma.3,23 Previously, YM155 IC50 values were reported to
range from 3.2 to 11 nM in melanoma cells24 and from 2 to
50 nM in multiple myeloma cells.25 In a screen of 124 cell lines
from 17 cancer entities, the YM155 IC50s ranged from 0.35 to
41000 nM.26 In a panel of 23 neuroblastoma cell lines, the
YM155 IC50s ranged from 0.5 to 410 000 nM.10 This shows
that the sensitivity to YM155-mediated survivin depletion may
substantially vary even in cells from the same cancer type.
Figure 6 Role of survivin in response to irradiation-induced DNA damage in neuroblastoma cells. (a) Representative western blots indicating cellular levels of γH2AX and
survivin 24 h after irradiation of UKF-NB-3 cells, UKF-NB-3 cells transduced with a lentiviral vector encoding shRNA directed against p53 (UKF-NB-3p53shRNA), or UKF-NB-3 cells
transduced with a control vector encoding non-targeting (‘scrambled’) shRNA (UKF-NB-3scrshRNA). β-actin served as a loading control. Quantitative, fluorescence-based western
blot analyses are presented in Supplementary Figure 6. (b) Viability of UKF-NB-3, UKF-NB-3p53shRNA, or UKF-NB-3scrshRNA cells 24 h post irradiation as indicated by MTTassay;
*P 0.05 relative to untreated control cells; (c) Combined effects of irradiation and YM155 on UKF-NB-3 (1 Gy, YM155 0.625 nM), UKF-NB-3p53shRNA (3 Gy, YM155 2.5 nM), or
UKF-NB-3scrshRNA (1 Gy, YM155 0.625 nM) cell viability 24 h post irradiation as indicated by MTT assay; *P 0.05 relative to either single treatment
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Hence, it will be critical to understand which cancer cells are
particularly sensitive to YM155 and survivin depletion in order
to design tailored therapies.
The parental cell lines UKF-NB-3 and UKF-NB-6 displayed
a similar response to YM155 treatment. The YM155 IC50s
were comparable (UKF-NB-3: 0.49± 0.10 nM; UKF-NB-6:
0.65±0.09 nM), and YM155 induced survivin depletion and
p53 induction in both cell lines. All investigated drug-resistant
sublines of UKF-NB-3 and UKF-NB-6 showed substantially
reduced YM155 sensitivity relative to the parental cell lines.
Three mechanisms may explain the decreased YM155
sensitivity in the drug-resistant cancer cell lines (at least to a
large degree): upregulation of ABCB1, downregulation of
SLC35F2, and loss of p53 function. Upregulation of the ABC
transporter ABCB1 had already been shown to affect the
efficacy of YM155.10,14 In accordance, the ABCB1 inhibitor
verapamil strongly decreased the YM155 IC50 values in the
ABCB1-expressing cell lines UKF-NB-3rVCR10 (from 26.59 to
1.95 nM), UKF-NB-6rDOX20 (from 11.80 to 1.35 nM), and
UKF-NB-6rVCR10 (from 49.30 to 3.60 nM), but not to the level
of the parental cell lines that displayed IC50 values of 0.49 nM
(UKF-NB-3) and 0.65 nM (UKF-NB-6). Hence, additional
resistance mechanisms appear to contribute to the decreased
YM155 sensitivity that was observed in the drug-resistant
neuroblastoma sublines in comparison to the respective
parental chemosensitive cells.
YM155 is transported by SLC35F2 into cells and lack of
SLC35F2 has been associated with decreased cellular
YM155 sensitivity.15 The drug-resistant neuroblastoma cell
lines UKF-NB-3rCDDP1000, UKF-NB-6rDOX20, and UKF-
NB-6rVCR20 were characterized by reduced SLC35F2
expression relative to the respective parental cells. Hence,
these decreased SLC35F2 levels are likely to contribute to the
increased YM155 resistance observed in these cell lineswhen
compared to the respective parental cell lines. This notion is
further supported by our finding that SLC35F2 depletion
Figure 7 Characterization of UKF-NB-3 cells that were adapted to growth in the presence of YM155 20 nM (UKF-NB-3rYM15520nM). (a) YM155 concentrations that reduce
UKF-NB-3 cell viability by 50% (IC50) in the presence or absence of the ABCB1 inhibitor verapamil (5 μM). Numerical values are presented in Supplementary Table 6. *Po0.05
relative to the YM155 IC50 in the absence of verapamil; (b) Representative western blots and fluorescence-based quantitative western blot analysis data indicating cellular protein
levels of ABCB1, SLC35F2, and survivin in UKF-NB-3 and UKF-NB-3rYM15520nM cells. *Po0.05 relative to UKF-NB-3 cells; (c) Cell viability in UKF-NB-3 and UKF-
NB-3rYM15520nM cells 48 h after transfection with siRNA directed against survivin or non-targeting ‘scrambled’ (scr) siRNA relative to untreated control cells. Numerical data are
presented in Supplementary Table 5. n.d.= non-detectable
Effects of YM155 on resistant neuroblastoma cells
Yvonne Voges et al
8
Cell Death and Disease
increases the resistance of ABCB1-expressing neuroblas-
toma cells. Since SLC35F2 and ABCB1 affect intracellular
YM155 concentrations, these represent drug-specific resis-
tance mechanisms that may not be shared by other
therapeutic strategies that target survivin.
UKF-NB-3rVCR10 was the only drug-resistant cell line that
did not display decreased SLC35F2 levels. However, ABCB1
inhibition did not resensitize UKF-NB-3rVCR10 cells to YM155
to the level of the parental UKF-NB-3 cell line. In contrast to the
other investigated cell lines, UKF-NB-3rVCR10 harbors a
C135F loss-of-function p53 mutation.16–18 Hence, loss of
p53 function may impair the YM155 sensitivity of neuroblas-
toma cells. Indeed, p53 depletion resulted in decreased
YM155 sensitivity of UKF-NB-3 and UKF-NB-6 cells. More-
over, the nutlin-3-resistant UKF-NB-3 subline UKF-
NB-3rNutlin10μM that harbors a G245C loss-of-function p53
mutation18 displayed reduced sensitivity to YM155 relative to
UKF-NB-3. Other reports had suggested that YM155 exerts its
anticancer effects independently of the cellular p53
status.26–28 However, the relevance of the p53 status for
cancer cell sensitivity to YM155 and survivin depletion may
depend on the cellular context.
The anticancer mechanism of action of YM155 has been
under dispute and may depend on the cellular background.
YM155 was introduced as a compound that suppresses the
expression of survivin.26 However, other studies suggested
that YM155 may primarily induce DNA damage and that the
reduction of survivin levels may rather be a consequence of
DNA damage.1,3,4 In our study, however, survivin down-
regulation preceded the occurrence of DNA damage in
response to YM155 treatment, suggesting that survivin
depletion happens prior to DNA damage formation. In
accordance, RNAi-mediated survivin depletion also resulted
in the induction of DNA damage, demonstrating that DNA
damage formation can be a consequence of the reduction of
cellular survivin levels. Notably, we and others had previously
shown that survivin depletion resulted in increased yH2AX foci
detection following irradiation29,30 that is functionally related to
a direct physical interrelationship of survivin with components
of DNA damage repair pathways.31,32
Mcl-1 was suggested as an alternative target of YM155.6
However, YM155 reduced cellular Mcl-1 levels at substantially
higher concentrations than survivin, and Mcl-1 depletion did
not affect neuroblastoma cell viability. The finding that Mcl-1
depletion does not impair neuroblastoma cell viability is in
accordance with previous results demonstrating that Mcl-1
depletion sensitizes neuroblastoma cells to paclitaxel, but
does not exert significant effects on neuroblastoma cell
viability on its own.33 Hence, the anti-neuroblastoma effects
of YM155 do not appear to be caused by Mcl-1 depletion.
Finally, survivin depletion-mediated X-linked inhibitor of
apoptosis (XIAP) degradation had been shown to contribute
to the effects of YM155 against breast cancer cells.34
However, survivin depletion did not decrease XIAP levels in
our models (Figures 2 and 5).
Neuroblastoma cells without functional p53 displayed not
only reduced sensitivity to YM155 but also to RNAi-mediated
survivin depletion. This suggests that loss of p53 function is a
target-specific resistance mechanism that is likely to generally
affect the efficacy of therapeutic approaches targeting
survivin. A role of p53 in the cellular response to survivin
depletion may not come too much as a surprise, given the
close interplay of survivin and p53.1,35 For example, survivin
depletion caused p53 activation in neuroblastoma cells not
only in our study but also in a previous study.9 In ALL cells,
survivin depletion-induced toxicity could be rescued by p53.36
Next, UKF-NB-3 cells were adapted to growth in the
presence of YM155 (20 nM, UKF-NB-3rYM15520nM) and the
resistance-associated changeswere investigated.We detected
a R248W p53 mutation as target-specific resistance mechan-
ism, and decreased SLC35F2 and increased ABCB1 as drug-
specific resistance mechanisms. UKF-NB-3rYM15520nM cells
also displayed decreased survivin levels and sensitivity to
RNAi-mediated survivin depletion relative to UKF-NB-3, further
confirming that YM155 primarily exerts its anti-neuroblastoma
effects through survivin depletion.
In conclusion, our data show that YM155 affects the viability
of neuroblastoma cells, including neuroblastoma cells with
acquired resistance to clinically relevant drugs through
survivin depletion and that survivin is a promising drug target
in neuroblastoma cells with acquired drug resistance. Cells
adaptated to YM155 displayed decreased survivin levels and
decreased sensitivity to RNAi-mediated survivin depletion,
confirming that YM155 targets survivin. Thus, cancer cell
adaptation to anticancer drugs represents a novel strategy to
elucidate the drug’s mechanism of action. Loss of p53 function
was determined as target-specific resistance mechanism that
generally affects therapeutic strategies directed against
survivin. Hence, survivin is particularly promising as drug
target for the treatment of p53 wild-type neuroblastomas,
including neuroblastomaswith acquired resistance to clinically
relevant anticancer drugs, potentially in combination with p53
activators such as MDM2 inhibitors that further enhance
YM155 activity. Notably, p53 wild-type neuroblastomas make
up the vast majority of neuroblastoma cases, as neuroblas-
tomas only rarely harbor p53 mutations.37,38
Materials and Methods
Drugs. YM155 (sepantronium bromide) was purchased from Selleck Chemicals
via BIOZOL Diagnostica GmbH (Eching, Germany), vincristine and cisplatin from
TEVA GmbH (Radebeul, Germany), doxorubicin from Cell Pharm (Bad Vilbel,
Germany), and verapamil from Sigma-Aldrich (Munich, Germany).
Cells. The MYCN-amplified neuroblastoma cell lines UKF-NB-3 and UKF-NB-6
were established from stage 4 neuroblastoma patients.16,39 UKF-NB-3 and UKF-
NB-6 sublines with acquired resistance to cisplatin (UKF-NB-3rCDDP1000),
doxorubicin (UKF-NB-6rDOX20), vincristine (UKF-NB-3rVCR10 and UKF-
NB-6rVCR10), or nutlin-3 (UKF-NB-3rNutlin10μM) were established by continuous
exposure to increasing drug concentrations as described previously16,18,39 and
derived from the Resistant Cancer Cell Line collection (www.kent.ac.uk/stms/cmp/
RCCL/RCCLabout.html).
All cells were propagated in Iscove’s modified Dulbecco’s medium supplemented
with 10% fetal calf serum, 100 IU/ml penicillin, and 100 mg/ml streptomycin at 37°C.
Cells were routinely tested for mycoplasma contamination and authenticated by short
tandem repeat profiling.
p53-depleted neuroblastoma cells or neuroblastoma cells showing high
expression of ABCB1 were established as described previously39–41, using the
Lentiviral Gene Ontology (LeGO) vector technology (www.lentigo-vectors.de).42
SLC35F2-depleted cells were established using the same technology. The shRNA
sequences (5′ to 3′) were sh1 SLC35F2, CTCTTTCTGTTTGGCTATA; sh2 SLC35F2,
GAGGAATACATCGTGAAGA; sh3 SLC35F2, CAGGGAGTGATGTATTGAT.
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Viability assay. Cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) dye reduction assay after 120 h incubation,
modified as described previously.18,39,41
RNA interference experiments. Transient depletion of SLC35F2 was
achieved using synthetic siRNA oligonucleotides (ON-TARGETplus SMARTpool)
from Dharmacon (Lafayette, CO, USA). Non-targeting siRNA (ON-TARGETplus
SMARTpool) was used as negative control. Cells were transfected by
electroporation using the NEON Transfection System (Invitrogen, Darmstadt,
Germany) according to the manufacturer protocol. Cells were grown to 60–80%
confluence, trypsinized, and 1.2 × 106 cells were resuspended in 200 μl
resuspension buffer R including 2.5 μM siRNA. The electroporation was performed
using two 20 ms pulses of 1400 V. Subsequently, the cells were transferred into cell
culture plates or flasks, containing prewarmed cell culture medium.
Western blot. Cells were lysed using Triton-X-100 sample buffer, and proteins
were separated by SDS-PAGE. Detection was done by using specific antibodies
against β-actin (Biovision through BioCat GmbH, Heidelberg, Germany), SLC35F2
(Santa Cruz Biotechnology, Dallas, TX, USA), ABCB1, Chk2, phosphorylated Chk2
(Thr68), Baculoviral IAP repeat containing 3 (cIAP-2), histone H2AX, phosphory-
lated histone H2AX (Ser139) (γH2AX), myeloid cell leukemia sequence-1 (Mcl-1),
p21, cleaved PARP, XIAP (all from Cell Signaling via New England Biolabs,
Frankfurt, Germany), p53 (Enzo Life Sciences, Lörrach, Germany), survivin and
Baculoviral IAP repeat containing 2 (cIAP-1) (R&D Systems, Minneapolis, MN,
USA). Protein bands were visualized by laser-induced fluorescence using infrared
scanner for protein quantification (Odyssey, Li-Cor Biosciences, Lincoln, NE, USA).
DNA damage kit. A DNA damage kit that determines apurinic/apyrimidinic sites
as indicators of DNA lesions by using an Aldehyde Reactive Probe (PromoKine,
Heidelberg, Germany) was used following the manufacturer’s instructions.
TP53 next-generation sequencing. All coding exonic and flanking intronic
regions of the human TP53 gene were amplified from genomic DNA with Platinum
Taq DNA polymerase (Life Technologies) by multiplex PCR, using two primer pools
with 12 non-overlapping primer pairs each, yielding ~ 180 bp amplicons. Each
sample was tagged with a unique 8-nucleotide barcode combination using twelve
differently barcoded forward and eight differently barcoded reverse primer pools.
Barcoded PCR products from up to 96 samples were pooled, purified, and an
indexed sequencing library was prepared using the NEBNext ChIP-Seq Library
Prep Master Mix Set for Illumina in combination with NEBNext Multiplex Oligos for
Illumina (New England Biolabs). The quality of sequencing libraries was verified on
a Bioanalyzer DNA High Sensitivity chip (Agilent) and quantified by digital PCR.
2 × 250 bp paired-end sequencing was carried out on an Illumina MiSeq (Illumina)
according to the manufacturer’s recommendations at a mean coverage of 300 × .
Read pairs were demultiplexed according to the forward and reverse primers and
subsequently aligned using the Burrows-Wheeler Aligner against the Homo sapiens
Ensembl reference (rev. 79). Overlapping mate pairs were combined and trimmed to
the amplified region. Coverage for each amplicon was calculated via SAMtools
(v1.1).43 To identify putative mutations, variant calling was performed using SAMtools
in combination with VarScan2 (v2.3.9).44 Initially, SAMtools was used to create
pileups with a base quality filter of 15. Duplicates, orphan reads, unmapped, and
secondary reads were excluded. Subsequently, Varscan2 was applied to screen for
SNPs and InDels separately, using a low-stringency setting with minimal variant
frequency of 0.1, a minimum coverage of 20, and a minimum of 10 supporting reads
per variant to account for cellular and clonal heterogeneity. Minimum average quality
was set to 20 and a strand filter was applied to minimize miscalls due to poor
sequencing quality or amplification bias. The resulting list of putative variants was
compared against the IARC TP53 (R17) database to check for known p53 cancer
mutations.
Statistics. Results are expressed as mean± S.D. of at least three experiments.
Comparisons between two groups were performed using Student’s t-test. Three and
more groups were compared by ANOVA followed by the Student–Newman–Keuls
test. P values lower than 0.05 were considered to be significant.
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